Roivant Sciences (ROIV) Amortizatization of Intangibles (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Amortizatization of Intangibles came in at $1.4 million in Q2 2026, down 28.26% on a YoY basis from $1.9 million in Q2 2025, and down 95.29% quarter-over-quarter from $29.6 million in Q4 2025.
Analysis
Roivant Sciences (ROIV) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Amortizatization of Intangibles for 6 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Amortizatization of Intangibles fell 28.26% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $51.9 million (down 36.17% YoY), and the FY2026 full-year result was $8.3 million, up 20.94% from the prior year.
- Amortizatization of Intangibles eased to $1.4 million in Q2 2026 per ROIV's latest filing, from $29.6 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $54.3 million in Q4 2024 and bottomed at $1.4 million in Q2 2026.
- Historically, Amortizatization of Intangibles has averaged $11.5 million across 5 years, with a median of $2.2 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles surged 1282.96% in 2024, then sank 45.48% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $6.0 million in 2022, then slipped by 16.01% to $5.0 million in 2023, then jumped by 975.97% to $54.3 million in 2024, then tumbled by 45.48% to $29.6 million in 2025, then sank by 95.29% to $1.4 million in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $1.4 million, $29.6 million, and $18.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 678,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Dec 31, 2025 | 29.61 Mn |
| Sep 30, 2025 | 18.94 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Dec 31, 2024 | 54.30 Mn |
| Sep 30, 2024 | 23.46 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Dec 31, 2023 | 5.05 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 2.19 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Dec 31, 2021 | 5.40 Mn |